Medicine & Life Sciences

1. Lymphoma, Large B-Cell, Diffuse 100%
2. Lymphoma 51%
3. Lenalidomide 40%
4. Follicular Lymphoma 38%
5. Rituximab 38%
6. Survival 32%
7. Progression-Free Survival 31%
8. Non-Hodgkin's Lymphoma 30%
9. B-Cell Lymphoma 29%
10. B-Lymphocytes 21%
11. B-Cell Chronic Lymphocytic Leukemia 21%
12. Therapeutics 16%
13. Clinical Trials 14%
14. Hodgkin Disease 14%
15. Cyclophosphamide 12%
16. Waldenstrom Macroglobulinemia 11%
17. Mantle-Cell Lymphoma 10%
18. Confidence Intervals 10%
19. Vincristine 10%
20. Neoplasms 10%
21. Recurrence 9%
22. Doxorubicin 9%
23. Multiple Myeloma 9%
24. Monocytes 9%
25. Molecular Epidemiology 9%
26. Prednisone 8%
27. T-Cell Lymphoma 8%
28. Stem Cell Transplantation 8%
29. Everolimus 8%
30. Bendamustine Hydrochloride 7%
31. Germinal Center 7%
32. Drug Therapy 7%
33. Peripheral T-Cell Lymphoma 7%
34. Anthracyclines 7%
35. Lymphocyte Count 6%
36. T-Lymphocytes 6%
37. Radioimmunotherapy 6%
38. ofatumumab 6%
39. Biomarkers 6%
40. Lymphocytes 5%
41. Mutation 5%
42. Medical Oncology 5%
43. Neurolymphomatosis 5%
44. Mechanistic Target of Rapamycin Complex 1 5%
45. Biopsy 5%
46. Central Nervous System 5%
47. Alemtuzumab 5%
48. Tumor Microenvironment 5%